MICHELLE BRANNAN: Open Payments
NPI 1588096028 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,280 in 95 payments from 22 companies in 2025. Trend: 2023 $3,610 · 2024 $2,422 · 2025 $2,280
Food & beverage: $2,180Education: $100
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 14 | $395 |
| Regeneron Healthcare Solutions, Inc. | 9 | $253 |
| GENZYME CORPORATION | 8 | $246 |
| ABBVIE INC. | 8 | $191 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | 11 | $155 |
| Galderma Laboratories, L.P. | 9 | $152 |
| Incyte Corporation | 5 | $133 |
| SANOFI-AVENTIS U.S. LLC | 1 | $100 |
| Amgen Inc. | 5 | $96 |
| LEO Pharma Inc. | 5 | $94 |
Products named: DUPIXENT, COSENTYX, Cabtreo, NEMLUVIO, OPZELURA, Rhapsido, SKYRIZI, OTEZLA.
Industry payments across TX — which companies pay providers there.
